| IUPAC name | [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid |
| canonical smiles | CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O |
| inchi | InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1 |
| inchi key | SGOIRFVFHAKUTI-ZCFIWIBFSA-N |
| molecular formula | C9H14N5O4P |
| synonyms | Tenofovir147127-20-6PMPA(R)-9-(2-Phosphonomethoxypropyl)adenine(R)-PMPA |
| Compound Description | Tenofovir is a member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [-1-propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis ester prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor, an antiviral drug and a drug metabolite. It is a member of phosphonic acids and a nucleoside analogue. It is a conjugate acid of a tenofovir.Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order to obtain oral bioavailability. |
